After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.
After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.
Share this Article
Recommended